Q1 2025 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius AG (SARTF) reported a strong start to 2025 with a 6.5% sales revenue growth in constant currencies.
- The Bioprocess Solutions division experienced a 10% increase in sales revenue, driven by strong double-digit growth in consumables.
- The company achieved a substantial margin expansion, with underlying EBITDA growing by 12.2% to EUR263 million.
- The acquisition of MatTek is expected to enhance Sartorius AG's portfolio, aligning with their innovation strategy and reducing reliance on animal testing.
- Strong cash flow and reduced leverage ratio were reported, indicating financial stability and effective management of resources.
- The Lab Products & Services (LPS) division faced challenges with a 5.5% decline in sales in constant currencies due to a soft equipment business.
- There is a continued reluctance from customers to make larger investments in equipment, impacting the LPS division.
- The company faces potential impacts from tariffs, although they do not expect it to affect their competitive positioning.
- China's business performance was slightly below the previous year, indicating regional challenges.
- The guidance for 2025 includes a cautious outlook with a sales revenue growth expectation of approximately 6%, reflecting market volatilities.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech conference call on the first quarter 2025. (Operator Instructions)
At this time, it's my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead, sir.
Thank you very much for the introduction. And hello and welcome to our conference call on the Q1 results of Sartorius AG, as well as Sartorius Stedim Biotech. Today, I'm together with Florian Funck, our CFO; as well as with René Fáber, the President of our Bioprocessing division, as well as the CEO of Sartorius Stedim Biotech; and also Alexandra Gatzemeyer, the President of our Lab division, as she will walk you through the slide on the most recently announced acquisition of MatTek.
So let me start with walking you through the highlights of the first quarter of 2025. We think we are off to a good start -- a very good start into the year 2025. Pretty much development has been as expected.
That means very much
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
